Royalty Pharma plc
RPRX
$31.28
$0.110.35%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -3.86% | -2.51% | -5.24% | -5.11% | 5.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.86% | -2.51% | -5.24% | -5.11% | 5.24% |
| Cost of Revenue | 30.64% | -48.00% | 2.33% | 22.31% | -38.00% |
| Gross Profit | -14.65% | 28.72% | -10.56% | -20.23% | 34.58% |
| SG&A Expenses | -5.24% | -13.47% | -11.07% | -15.20% | 9.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.61% | -44.95% | -2.35% | 10.38% | -34.38% |
| Operating Income | -13.38% | 52.49% | -8.83% | -20.53% | 61.68% |
| Income Before Tax | -21.72% | 360.18% | 118.72% | 94.20% | 638.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.72% | 360.18% | 118.72% | 94.20% | 638.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 16.53% | -202.53% | -65.17% | -38.90% | -201.90% |
| Net Income | -24.31% | 520.96% | 164.07% | 140.75% | 2,549.50% |
| EBIT | -13.38% | 52.49% | -8.83% | -20.53% | 61.68% |
| EBITDA | -- | -39.58% | -27.35% | -14.04% | 61.31% |
| EPS Basic | -28.90% | 540.84% | 167.31% | 136.18% | 2,196.11% |
| Normalized Basic EPS | -26.68% | -30.33% | -68.48% | -80.63% | -19.70% |
| EPS Diluted | -28.88% | 6,510.78% | 1,107.22% | 460.77% | 875.83% |
| Normalized Diluted EPS | -18.61% | -40.86% | -73.27% | -83.32% | -33.46% |
| Average Basic Shares Outstanding | 8.15% | 0.36% | 0.93% | 1.70% | 2.20% |
| Average Diluted Shares Outstanding | -1.48% | 5.68% | 5.76% | 6.10% | 6.53% |
| Dividend Per Share | 5.00% | 5.06% | 5.13% | 5.19% | 5.26% |
| Payout Ratio | 0.39% | -0.83% | -0.60% | -0.56% | -0.96% |
